Pharma calls in sick after Trump’s 100% tariff threat

The Indian pharma sector is highly dependent on exports, particularly to the US. Any protectionist measures from the US, like tariffs, directly threaten revenue and profit margins for many Indian drug manufacturers.

Maintain a bearish bias on Indian pharma stocks, especially those with high US revenue concentration, until clarity emerges on potential tariffs.

For Indian markets, this story mainly matters for the Pharmaceuticals pocket. The current signal is bearish, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •Pharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs.
• •Tariffs would be on imported branded and patented medicine makers.
• •The news spooked investors in a weak market.
• •Risk flag: Uncertainty regarding the actual implementation and scope of tariffs.
• •Risk flag: Potential for retaliatory measures or diplomatic resolutions.